Cargando…

Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention

Background: Patients with diabetes mellitus (DM) are considered to increase the risk of thrombosis and bleeding. However, whether DM is an independent risk factor for events in patients anticoagulated with bivalirudin during elective percutaneous coronary intervention (PCI) is not clear. Methods: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yulong, Li, Jiawen, Guan, Changdong, Su, Shuhong, Wang, Zhifang, Liu, Haiwei, Xu, Bo, Yang, Weixian, Yang, Yuejin, Gao, Runlin, Yuan, Jinqing, Zhao, Xueyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Manuscript
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9373170/ https://www.ncbi.nlm.nih.gov/pubmed/35942867 http://dx.doi.org/10.1177/10760296221113344

Ejemplares similares

Five-Year Prognostic Value of DAPT Score in Older Patients undergoing Percutaneous Coronary Intervention: A Large-Sample Study in the Real World
por: Yan, Kailun, et al.
Publicado: (2023)

Remnant cholesterol but not LDL cholesterol is associated with 5-year bleeding following percutaneous coronary intervention
por: Li, Jiawen, et al.
Publicado: (2023)

A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
por: Li, Jiawen, et al.
Publicado: (2023)

Novel Platelet Function Analyzer 200 Predicts Blood Transfusion After Elective Cardiac Surgery in Patients Suspended on Dual Antiplatelet Therapy
por: Cui, Wen, et al.
Publicado: (2023)

Combined effect of D-dimer, hs-CRP, and Lp(a) on 5-year clinical outcomes after percutaneous coronary intervention: A large real-world study in China
por: Li, Jiawen, et al.
Publicado: (2023)

Predictors and Outcomes of Secondary Prevention Medication in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Tianyu, et al.
Publicado: (2021)

Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Wang, Zheng-Dong, et al.
Publicado: (2022)

Is it time to switch to bivalirudin for ECMO anticoagulation?
por: Navaei, Amir, et al.
Publicado: (2023)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Long-Term Clinical Outcomes for Non-ST Elevation Acute Coronary Syndrome Patients with High-Risk Angiographic Findings Undergoing Percutaneous Coronary Intervention
por: Jia, Sida, et al.
Publicado: (2020)

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017)

Selection of an Aptamer Antidote to the Anticoagulant Drug Bivalirudin
por: Martin, Jennifer A., et al.
Publicado: (2013)

D-dimer as a thrombus biomarker for predicting 2-year mortality after percutaneous coronary intervention
por: Zhao, Xueyan, et al.
Publicado: (2020)

Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China
por: Li, Jiawen, et al.
Publicado: (2021)

High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort
por: Wang, Peizhi, et al.
Publicado: (2022)

Machine learning for prediction of bleeding in acute myocardial infarction patients after percutaneous coronary intervention
por: Zhao, Xueyan, et al.
Publicado: (2023)

Primary bivalirudin anticoagulation for patients with an implantable ventricular assist device
por: Pieri, M, et al.
Publicado: (2014)

Evidence-based oral antiplatelet therapy among hospitalized Chinese patients with acute myocardial infarction: results from the Chinese acute myocardial infarction registry
por: Tang, Xiaofang, et al.
Publicado: (2021)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Zhang, Juan, et al.
Publicado: (2017)

High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions
por: Urban, Lukáš, et al.
Publicado: (2023)

Periprocedural anticoagulation in transcatheter aortic valve replacement: Heparin vs bivalirudin
por: Minhas, Abdul Mannan Khan, et al.
Publicado: (2017)

Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Ahmad Hamdi, Abdul Hafeez, et al.
Publicado: (2017)

Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention
por: Zhao, Xueyan, et al.
Publicado: (2019)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation
por: Ranucci, Marco, et al.
Publicado: (2011)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19
por: Seelhammer, Troy G., et al.
Publicado: (2021)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
por: Trigonis, Russell, et al.
Publicado: (2022)

Safety profile of bivalirudin in Chinese female patients undergoing percutaneous coronary intervention: a multi-center study
por: Wu, Fan, et al.
Publicado: (2022)

Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion
por: Zhang, Xiaochun, et al.
Publicado: (2021)

Long-Term Clinical Outcomes of Unprotected Left Main Percutaneous Coronary Intervention: A Large Single-Centre Experience
por: Gao, Lijian, et al.
Publicado: (2021)

Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis
por: Lee, Wei-Chieh, et al.
Publicado: (2023)

Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives.
por: Galasso, G, et al.
Publicado: (2016)

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)

Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention: a real-world study
por: Wang, Ping, et al.
Publicado: (2022)

The Prognostic Value of a Derived Neutrophil-Lymphocyte Ratio in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Fan, Wenjun, et al.
Publicado: (2021)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study
por: Zhang, Chi, et al.
Publicado: (2022)

Management of Haemarthrosis in Patients On Oral Anticoagulants
por: Dalrymple, James, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8harc4v98sqfetu1n3tvk0vtaj